Function of SLAM family molecules in tumor microenvironment and development of new therapeutic strategies in myeloma
| Project/Area Number |
26461433
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
Tamura Hideto 日本医科大学, 医学部, 准教授 (70256949)
|
|---|
| Research Collaborator |
ISIBASHI Mariko
OKUYAMA Namiko
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 多発性骨髄腫 / SLAMファミリー分子 / 腫瘍微小環境 / 免疫治療 / SLAMF分子 / CD229 / SLAMF7 / SLAMファミリー |
|---|
| Outline of Final Research Achievements |
SLAMF3/7 are highly expressed on multiple myeloma (MM) cells, although their role in MM pathogenesis remains unclear. In this study, we investigated the functions of those molecules to elucidate MM pathophysiology and attempted to develop new therapeutic strategies. High levels of SLAMF expression were detected in most patients. The proliferative potential and percentage of antimyeloma drug-induced apoptotic cells in SLAMF+ MM cells were significantly higher and lower than in SLAMF- cells, respectively. And we identified new adaptor proteins that could mediate activation signaling in MM cells. The serum levels of soluble SLAMF in MM patients were significantly higher than in healthy controls. in vitro study showed that the combination of FITC-conjugated anti-SLAMF7 antibody and FITC-targeted CART cells induced specific lysis of SLAMF7+ MM cells. Our results demonstrated that SLAMFs could be good targets for immunotherapies including antibody treatment and T cell-mediated immunotherapy.
|
Report
(4 results)
Research Products
(12 results)
